secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2021-07-29T23:59:59+00:00
Accession:  0001193125-21-229184
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotechnology enters $100M note purchase agreement to refinance prior credit facility
--------------------------------------------------------------------------------

- Issued $100M notes to Athyrium; $25M additional available; used proceeds plus ~$9.2M to repay prior $100M facility.
- Notes bear 8.0% + 3-month LIBOR; quarterly interest; principal amortization starts June 2024, maturity July 2026.
- Covenants require minimum cash and minimum NERLYNX-based revenue; secured by substantially all assets including IP.
- Prepayment fees: make-whole within 2 years, 2% thereafter to year 3; exit fee 2% on any prepayment.
- Restrictions on additional debt, dividends, mergers, asset sales, and change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000119312521229184/0001193125-21-229184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000119312521229184/d155853d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-229184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer